Acute pancreatitis, gallbladder disease, and stomach paralysis have also been rarely reported with GLP-1 use
*Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity
The following represent the primary codes relevant to amputation management, drawn from the CMS HCPCS 2026 code set
Limitations Side effects can be more pronounced initially (nausea, diarrhea)
This up-and-coming molecule is already making headlines with its unique blend of action and weight management potential, dazzling audiences and critics alike
19 In regard to CKD, these clinical trials have also shown positive effects in the composite renal outcomes